Business
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – –
About this update from Connect Biopharma Holdings Limited
[{"type":"text","content":"– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan for rademikibart; expect to initiate parallel Phase 2 trials in 2Q25 – SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the Company will present four posters at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco. The following abstracts are posted on ATS 2025’s online itinerary planner for registered users: Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe AsthmaPresenter: Raúl Collazo, Ph.D.Session A32: It’s Not Easy Being Wheezy: Asthma and COPD Clinical StudiesFormat: Thematic Poster SessionPoster #: P1386Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT Title: Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is There an IL-4Rα Class Effect?Presenter: Michael Wechsler, M.D.Session A33: Biomarker Window into Lung DiseaseFormat: Thematic Poster SessionPoster #: P1515Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT Title: Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex Presenter: Raúl Collazo, Ph.D.Session A34: Winning the Biologic Battle in Asthma and COPDFormat: Thematic Poster SessionPoster #: P1439Date and Time: Sunday, May 18, 2025, from 11:30 a.m. – 1:15 p.m. PT Title: Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma Presenter: Michael Wechsler, M.D.Session B101: Fixing Barriers: Unlocking Treatment Modalities in Inflammatory Lung DiseasesFormat: Poster Discussion SessionPoster #: 1020Date and Time: Monday, May 19, 2025: Viewing: 2:15 p.m. – 3:00 p.m. PT | Discussion: 3:15 p.m. – 4:15 p.m. PT Following the presentations, each poster will be available on Connect’s website under the Presentations and Publications section. About Connect Biopharma ...